Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CYTK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aficamten FDA approved Dec 2025 · Myqorzo |
Hypertrophic Cardiomyopathy (HCM) | Phase 4 · NCT07600177 | Recruiting |
| Tirasemtiv | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 · NCT02936635 | Completed |
| Omecamtiv Mecarbil | Heart Failure With Reduced Ejection Fraction | Phase 3 · NCT03759392 | Completed |
| Reldesemtiv | Amyotrophic Lateral Sclerosis | Phase 3 · NCT04944784 | Terminated |
| CK-3773274 | Hypertrophic Cardiomyopathy (HCM) | Phase 2 · NCT04219826 | Completed |
| Ulacamten | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 · NCT06793371 | Recruiting |
| Omecamtiv Mecarbil Matrix F1 Formulation | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| Omecamtiv Mecarbil Matrix F2 Formulation | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| Omecamtiv Mecarbil Swellable Core Technology F2 | Modified Release Oral Formulation | Phase 2 · NCT01786512 | Completed |
| KSP Inhibitor SB-743921 | Non-Hodgkin's Lymphoma | Phase 1/2 · NCT00343564 | Completed |
| CK-1827452 | Heart Failure | Phase 2 · NCT00624442 | Completed |
| Moxifloxacin | QT Intervals Changes | Phase 1 · NCT04175808 | Completed |
| AMG 423 | Heart Failure | Phase 1 · NCT01737866 | Completed |
| Ispinesib | Breast Neoplasms | Phase 1 · NCT00607841 | Terminated |
| CK-3773274 - Granules in Capsule | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 1 · NCT03767855 | Completed |
| CK-4021586 | Healthy Participants | Phase 1 · NCT05877053 | Completed |
Also used in these trials (approved or third-party drugs, not CYTK's own candidates): Metoprolol Succinate Er, Riluzole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CYTK holds $1.6B in cash and short-term investments (as of Sep 30, 2026) and burns about $141.9M/quarter from operations, an estimated runway of 33.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CYTK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 21,041,152 | 15.10% | 2026-09-30 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 17,716,372 | 12.72% | 2025-12-31 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 10,742,652 | 7.71% | 2026-09-30 |
| Polar Capital Holdings PLC | Institution (13F) | 9,635,314 | 6.92% | 2026-09-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 7,143,229 | 5.13% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 6,799,536 | 4.88% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 6,422,042 | 4.61% | 2026-03-31 |
| Avoro Capital Advisors LLC | Institution (13F) | 4,900,000 | 3.52% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 4,735,328 | 3.40% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 3,767,864 | 2.70% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 3,016,565 | 2.17% | 2026-09-30 |
| Robert I Blum President & CEO, Director · +247,774 options |
Insider | 282,710 | 0.20% | 2026-11-02 |
Share count 139,303,351 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-09 filed 2026-11-12 |
PARSHALL B LYNNE |
Sale (S) | 2,445 | $54.17 | 8,339 |
| 2026-11-09 filed 2026-11-12 |
PARSHALL B LYNNE |
Sale (S) | 2,555 | $55.26 | 5,784 |
| 2026-11-03 filed 2026-11-03 |
Malik Fady Ibraham |
Option exercise (M) | 3,500 | $7.80 | 157,402 |
| 2026-11-03 filed 2026-11-03 |
Malik Fady Ibraham |
Sale (S) | 3,500 | $62.93 | 153,902 |
| 2026-11-03 filed 2026-11-03 |
Malik Fady Ibraham |
Option exercise (M) | 3,500 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-11-14 | aficamten | sNDA | -12.2% | — | — |
| 2025-12-26 | MYQORZO | NDA | -4.5% | -1.7% | -3.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CYTK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →